⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RARE News
Ultragenyx Pharmaceutical Inc.
Form 8-K
sec.gov
RARE
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
globenewswire.com
RARE
RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Ultragenyx Pharmaceutical Inc. to Contact the Firm Today!
accessnewswire.com
RARE
Pomerantz LLP Notifies Investors of Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. – RARE
accessnewswire.com
RARE
RARE DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE
accessnewswire.com
RARE
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm
globenewswire.com
RARE
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Ultragenyx Lawsuit - RARE
prnewswire.com
RARE
ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ: RARE) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by April 6, 2026
globenewswire.com
RARE
Class Action Lawsuit Reminder from Pomerantz LLP for Shareholders of Ultragenyx Pharmaceutical Inc. – RARE
accessnewswire.com
RARE
RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Ultragenyx Pharmaceutical Inc. to Contact the Firm Today!
accessnewswire.com
RARE